New eye drops aim to calm Sjögren's dry eye by blocking inflammation
NCT ID NCT07671222
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether eye drops containing infliximab, a drug that blocks a key inflammatory protein, can safely improve severe dry eye in people with Sjögren's syndrome. 38 adults will receive either the active drops or a steroid drop for 6 weeks. The study measures symptom changes and eye surface health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
infliximab eye drops
What this could lead to
If it works, this could offer a new, safer option for managing severe dry eye in Sjögren's syndrome by targeting inflammation directly.
What could go wrong
This is a small early-phase trial with only 38 people, so results may not apply widely. The treatment is topical but still carries risks like infection or irritation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SJOGREN SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Instituto de Oftalmología Conde de Valenciana
Mexico City, Mexico City, 06800, Mexico